NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
EpicentRx, Inc.
Calithera Biosciences, Inc
Peregrine Pharmaceuticals
Hoffmann-La Roche
Bayer
Bristol-Myers Squibb